GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
R&D Expense Growth
17.56%
Fiscal year · Period ending:
GSK R&D Expense Growth
Latest reported17.56%period ending
Latest reported17.56%period ending
GSK FY R&D Growth (YoY) (0.00% → 17.56%)
Latest values, visible window
High-resolution chart · PNG
GSK r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 17.5598% | |
| 2.8604% | |
| 13.3929% | |
| 9.3445% | |
| 4.7152% | |
| 4.9256% | |
| 17.3388% | |
| -13.025% | |
| 23.3738% | |
| 1.9101% | |
| 3.1884% | |
| -12.0571% | |
| -1.4074% | |
| -0.7483% | |
| -10.0516% | |
| 8.5485% | |
| 11.5458% | |
| 13.6002% | |
| -6.2406% | |
| 10.2262% | |
| 8.0066% | |
| 4.1553% | |
| -3.8924% | |
| 13.2413% | |
| 1.3818% | |
| 99.0544% | |
| 9.1144% | |
| 1.3066% | |
| -1.1197% | |
| -24.6104% | |
| 0% | |
| -100% | |
| 16.1028% | |
| 24.2017% | |
| 25.2632% | |
| 13.0952% | |
| 30.031% | |
| 40.4348% | |
| 54.3624% | |
| 31.8584% | |
| 0% |